Q3 2024 · 13F-HR
Patient Square Capital LPholdings as filed
Filed 2024-11-14 · accession 0000950123-24-011804
$269.4M
Reported value
11
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $141.1M | 52.4% | 12,228,465 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $71.8M | 26.7% | 7,182,532 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS, INC. | $13.8M | 5.12% | 824,705 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $12.5M | 4.65% | 171,704 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS | $10.9M | 4.04% | 1,361,979 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS, INC. | $7.3M | 2.72% | 325,789 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N.V. | $4.5M | 1.67% | 242,341 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS, INC. | $2.6M | 0.98% | 128,569 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS, INC. | $2.3M | 0.86% | 90,572 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX, INC. | $2.0M | 0.76% | 235,498 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS, INC. | $434,036 | 0.16% | 39,422 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.